{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T09:58:13Z","timestamp":1777111093958,"version":"3.51.4"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T00:00:00Z","timestamp":1749254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T00:00:00Z","timestamp":1749254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100018684","name":"National Health Commission of the People's Republic of China","doi-asserted-by":"publisher","award":["NIHAYS2326"],"award-info":[{"award-number":["NIHAYS2326"]}],"id":[{"id":"10.13039\/501100018684","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Chinese Pharmacological Society","award":["ADR2024MS01\u2043ADR2024MS27"],"award-info":[{"award-number":["ADR2024MS01\u2043ADR2024MS27"]}]},{"name":"Chinese Pharmaceutical Society","award":["CPA\u2043Z05\u2043ZC\u20432023\u2043002"],"award-info":[{"award-number":["CPA\u2043Z05\u2043ZC\u20432023\u2043002"]}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2020YFC2008305"],"award-info":[{"award-number":["2020YFC2008305"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s00228-025-03863-1","type":"journal-article","created":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T15:04:33Z","timestamp":1749308673000},"page":"1207-1216","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Literature-based case analysis of serious adverse drug events associated with edoxaban"],"prefix":"10.1007","volume":"81","author":[{"given":"Xuanyu","family":"Luan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongyang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3843-8767","authenticated-orcid":false,"given":"Qingxia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,7]]},"reference":[{"key":"3863_CR1","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s00392-017-1102-5","volume":"106","author":"R De Caterina","year":"2017","unstructured":"De Caterina R, Lip GYH (2017) The non-vitamin K antagonist oral anticoagulants (NOACs) and extremes of body weight-a systematic literature review. Clin Res Cardiol 106:565\u2013572. https:\/\/doi.org\/10.1007\/s00392-017-1102-5","journal-title":"Clin Res Cardiol"},{"key":"3863_CR2","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Eugene B et al (2013) Edoxaban versus Warfarin in patients with Atrial Fibrillation. N Engl J Med 369:2093\u20132104. https:\/\/doi.org\/10.1056\/NEJMoa1310907","journal-title":"N Engl J Med"},{"key":"3863_CR3","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","volume":"369","author":"The Hokusai-VTE Investigators","year":"2013","unstructured":"The Hokusai-VTE Investigators (2013) Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism. N Engl J Med 369:1406\u20131415. https:\/\/doi.org\/10.1056\/NEJMoa1306638","journal-title":"N Engl J Med"},{"key":"3863_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci11010030","volume":"11","author":"G Frisullo","year":"2020","unstructured":"Frisullo G, Profice P, Brunetti V et al (2020) Prospective Observational Study of Safety of Early Treatment with Edoxaban in Patients with Ischemic Stroke and Atrial Fibrillation (SATES Study). Brain Sci 11:30. https:\/\/doi.org\/10.3390\/brainsci11010030","journal-title":"Brain Sci"},{"key":"3863_CR5","unstructured":"China Medical Education Association (2023) Specification for risk management of high alert medications in medical institutions"},{"key":"3863_CR6","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","volume":"356","author":"IR Edwards","year":"2000","unstructured":"Edwards IR, Aronson JK (2000) Adverse drug reactions: definitions, diagnosis, and management. Lancet 356:1255\u20131259. https:\/\/doi.org\/10.1016\/S0140-6736(00)02799-9","journal-title":"Lancet"},{"key":"3863_CR7","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) (2016) ICH harmonised guideline: Integrated addendum to ICH E6(R1): Guideline for good clinical practice E6(R2)."},{"key":"3863_CR8","unstructured":"U.S. Food and Drug Administration website (2021) GENENTECH Company. RITUXAN (Rituximab). [package insert]"},{"key":"3863_CR9","unstructured":"Lixiana 15mg Film-Coated Tablets - Summary of Product Characteristics (SmPC) - (emc). https:\/\/www.medicines.org.uk\/emc\/product\/6907\/smpc. Accessed 11 Jan 2025"},{"key":"3863_CR10","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1093\/europace\/euab065","volume":"23","author":"J Steffel","year":"2021","unstructured":"Steffel J, Collins R, Antz M et al (2021) 2021 European heart rhythm association practicalguide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace 23:1612\u20131676. https:\/\/doi.org\/10.1093\/europace\/euab065","journal-title":"Europace"},{"key":"3863_CR11","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","volume":"123","author":"R Mehran","year":"2011","unstructured":"Mehran R, Rao SV, Bhatt DL et al (2011) Standardized bleeding definitions for cardiovascular clinical trials. Circulation 123:2736\u20132747. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.110.009449","journal-title":"Circulation"},{"key":"3863_CR12","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.015689","volume":"9","author":"CM Yong","year":"2020","unstructured":"Yong CM, Tremmel JA, Lansberg MG et al (2020) Sex differences in oral anticoagulation and outcomes of stroke and intracranial bleeding in newly diagnosed atrial fibrillation. J Am Heart Assoc 9:e015689. https:\/\/doi.org\/10.1161\/JAHA.120.015689","journal-title":"J Am Heart Assoc"},{"key":"3863_CR13","doi-asserted-by":"publisher","unstructured":"Proietti M, Cheli P, Basili S, Mazurek M and Lip GY (2017) Balancing thromboembolic and bleeding risk with non-vitamin K antagonist oral anticoagulants (NOACs): a systematic review and meta-analysis on gender differences. Pharmacol Res 117:274\u2013282. https:\/\/doi.org\/10.1016\/j.phrs.2017.01.004","DOI":"10.1016\/j.phrs.2017.01.004"},{"key":"3863_CR14","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1161\/CIRCULATIONAHA.120.052216","volume":"143","author":"TA Zelniker","year":"2021","unstructured":"Zelniker TA, Ardissino M, Andreotti F et al (2021) Comparison of the efficacy and safety outcomes of Edoxaban in 8040 women versus 13 065 men with atrial fibrillation in the ENGAGE AF-TIMI 48 Trial. Circulation 143:673\u2013684. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.052216","journal-title":"Circulation"},{"key":"3863_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1110036","volume":"14","author":"M Giner-Soriano","year":"2023","unstructured":"Giner-Soriano M, Prat-Vallverd\u00fa O, Ouchi D et al (2023) Sex and gender differences in the use of oral anticoagulants for non-valvular atrial fibrillation: a population-based cohort study in primary health care in catalonia. Front Pharmacol 14:1110036. https:\/\/doi.org\/10.3389\/fphar.2023.1110036","journal-title":"Front Pharmacol"},{"key":"3863_CR16","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1093\/eurheartj\/ehy807","volume":"40","author":"T-F Chao","year":"2019","unstructured":"Chao T-F, Chen S-A, Ruff CT et al (2019) Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial. Eur Heart J 40:1518\u20131527. https:\/\/doi.org\/10.1093\/eurheartj\/ehy807","journal-title":"Eur Heart J"},{"key":"3863_CR17","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1056\/NEJMoa2012883","volume":"383","author":"K Okumura","year":"2020","unstructured":"Okumura K, Akao M, Yoshida T et al (2020) Low-dose Edoxaban in very elderly patients with atrial fibrillation. N Engl J Med 383:1735\u20131745. https:\/\/doi.org\/10.1056\/NEJMoa2012883","journal-title":"N Engl J Med"},{"key":"3863_CR18","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.003432","volume":"5","author":"ET Kato","year":"2016","unstructured":"Kato ET, Giugliano RP, Ruff CT et al (2016) Efficacy and safety of Edoxaban in elderly patients with atrial fibrillation in the ENGAGE AF-TIMI 48 Trial. J Am Heart Assoc 5:e003432. https:\/\/doi.org\/10.1161\/JAHA.116.003432","journal-title":"J Am Heart Assoc"},{"key":"3863_CR19","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1016\/S0140-6736(14)61943-7","volume":"385","author":"CT Ruff","year":"2015","unstructured":"Ruff CT, Giugliano RP, Braunwald E et al (2015) Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet 385:2288\u20132295. https:\/\/doi.org\/10.1016\/S0140-6736(14)61943-7","journal-title":"Lancet"},{"key":"3863_CR20","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1111\/bcp.14623","volume":"87","author":"OS Lee","year":"2021","unstructured":"Lee OS, Kim W, Jang BM et al (2021) Association of risk factors and bleeding complications in Asian patients taking edoxaban. Br J Clin Pharmacol 87:2121\u20132127. https:\/\/doi.org\/10.1111\/bcp.14623","journal-title":"Br J Clin Pharmacol"},{"key":"3863_CR21","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31\u201341. https:\/\/doi.org\/10.1159\/000180580","journal-title":"Nephron"},{"key":"3863_CR22","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1177\/0091270009351883","volume":"50","author":"K Ogata","year":"2010","unstructured":"Ogata K, Mendell-Harary J, Tachibana M et al (2010) Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 50:743\u2013753. https:\/\/doi.org\/10.1177\/0091270009351883","journal-title":"J Clin Pharmacol"},{"key":"3863_CR23","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1161\/CIRCULATIONAHA.116.022361","volume":"134","author":"EA Bohula","year":"2016","unstructured":"Bohula EA, Giugliano RP, Ruff CT et al (2016) Impact of renal function on outcomes with Edoxaban in the ENGAGE AF-TIMI 48 Trial. Circulation 134:24\u201336. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.022361","journal-title":"Circulation"},{"key":"3863_CR24","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s40265-020-01328-6","volume":"80","author":"A Corsini","year":"2020","unstructured":"Corsini A, Ferri N, Proietti M, Boriani G (2020) Edoxaban and the issue of drug-drug interactions: from pharmacology to clinical practice. Drugs 80:1065\u20131083. https:\/\/doi.org\/10.1007\/s40265-020-01328-6","journal-title":"Drugs"},{"key":"3863_CR25","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1126\/science.1168750","volume":"323","author":"SG Aller","year":"2009","unstructured":"Aller SG, Yu J, Ward A et al (2009) Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 323:1718\u20131722. https:\/\/doi.org\/10.1126\/science.1168750","journal-title":"Science"},{"key":"3863_CR26","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1177\/0897190018788264","volume":"33","author":"Y Mo","year":"2020","unstructured":"Mo Y, Karakas-Torgut A, Pham AQ (2020) Evaluation of potential drug-drug interactions with direct oral anticoagulants in a large urban hospital. J Pharm Pract 33:136\u2013141. https:\/\/doi.org\/10.1177\/0897190018788264","journal-title":"J Pharm Pract"},{"key":"3863_CR27","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1093\/eurheartj\/ehn139","volume":"29","author":"R Nieuwlaat","year":"2008","unstructured":"Nieuwlaat R, Prins MH, Le Heuzey J-Y et al (2008) Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the euro heart survey on atrial fibrillation. Eur Heart J 29:1181\u20131189. https:\/\/doi.org\/10.1093\/eurheartj\/ehn139","journal-title":"Eur Heart J"},{"key":"3863_CR28","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s40256-013-0029-0","volume":"13","author":"J Mendell","year":"2013","unstructured":"Mendell J, Zahir H, Matsushima N et al (2013) Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs 13:331\u2013342. https:\/\/doi.org\/10.1007\/s40256-013-0029-0","journal-title":"Am J Cardiovasc Drugs"},{"key":"3863_CR29","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1160\/TH11-08-0566","volume":"107","author":"DE Salazar","year":"2012","unstructured":"Salazar DE, Mendell J, Kastrissios H et al (2012) Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation. Thromb Haemost 107:925\u2013936. https:\/\/doi.org\/10.1160\/TH11-08-0566","journal-title":"Thromb Haemost"},{"key":"3863_CR30","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1093\/eurheartj\/ehv201","volume":"36","author":"J Steffel","year":"2015","unstructured":"Steffel J, Giugliano RP, Braunwald E et al (2015) Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial. Eur Heart J 36:2239\u20132245. https:\/\/doi.org\/10.1093\/eurheartj\/ehv201","journal-title":"Eur Heart J"},{"key":"3863_CR31","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1093\/europace\/euz193","volume":"21","author":"G Boriani","year":"2019","unstructured":"Boriani G, Blomstr\u00f6m-Lundqvist C, Hohnloser SH et al (2019) Safety and efficacy of dronedarone from clinical trials to real-world evidence: implications for its use in atrial fibrillation. Europace 21:1764\u20131775. https:\/\/doi.org\/10.1093\/europace\/euz193","journal-title":"Europace"},{"key":"3863_CR32","doi-asserted-by":"publisher","unstructured":"January CT, Wann LS, Calkins H, et al (2019) 2019 AHA\/ACC\/HRS Focused Update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the american college of cardiology\/american heart association task force on clinical practice guidelines and the heart rhythm society in collaboration with the society of thoracic surgeons. circulation 140:. https:\/\/doi.org\/10.1161\/CIR.0000000000000665","DOI":"10.1161\/CIR.0000000000000665"},{"key":"3863_CR33","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.thromres.2022.08.007","volume":"218","author":"H-N Wen","year":"2022","unstructured":"Wen H-N, He Q-F, Xiang X-Q et al (2022) Predicting drug-drug interactions with physiologically based pharmacokinetic\/pharmacodynamic modelling and optimal dosing of apixaban and rivaroxaban with dronedarone co-administration. Thromb Res 218:24\u201334. https:\/\/doi.org\/10.1016\/j.thromres.2022.08.007","journal-title":"Thromb Res"},{"key":"3863_CR34","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s10557-023-07443-2","volume":"38","author":"A Lenard","year":"2024","unstructured":"Lenard A, Hermann SA, Stoll F et al (2024) Effect of clarithromycin, a strong CYP3A and P-glycoprotein inhibitor, on the pharmacokinetics of Edoxaban in healthy volunteers and the evaluation of the drug interaction with other oral factor xa inhibitors by a microdose cocktail approach. Cardiovasc Drugs Ther 38:747\u2013756. https:\/\/doi.org\/10.1007\/s10557-023-07443-2","journal-title":"Cardiovasc Drugs Ther"},{"key":"3863_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14061120","volume":"14","author":"N Ferri","year":"2022","unstructured":"Ferri N, Colombo E, Tenconi M et al (2022) Drug-Drug Interactions of Direct Oral Anticoagulants (DOACs): from pharmacological to clinical practice. Pharmaceutics 14:1120. https:\/\/doi.org\/10.3390\/pharmaceutics14061120","journal-title":"Pharmaceutics"},{"key":"3863_CR36","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s40261-015-0298-2","volume":"35","author":"J Mendell","year":"2015","unstructured":"Mendell J, Chen S, He L et al (2015) The effect of rifampin on the pharmacokinetics of edoxaban in healthy adults. Clin Drug Investig 35:447\u2013453. https:\/\/doi.org\/10.1007\/s40261-015-0298-2","journal-title":"Clin Drug Investig"},{"key":"3863_CR37","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s40262-015-0342-7","volume":"55","author":"DA Parasrampuria","year":"2016","unstructured":"Parasrampuria DA, Truitt KE (2016) Pharmacokinetics and pharmacodynamics of Edoxaban, a Non-Vitamin K antagonist oral anticoagulant that inhibits clotting factor Xa. Clin Pharmacokinet 55:641\u2013655. https:\/\/doi.org\/10.1007\/s40262-015-0342-7","journal-title":"Clin Pharmacokinet"},{"key":"3863_CR38","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1124\/dmd.113.054866","volume":"42","author":"T Mikkaichi","year":"2014","unstructured":"Mikkaichi T, Yoshigae Y, Masumoto H et al (2014) Edoxaban transport via P-glycoprotein is a key factor for the drug\u2019s disposition. Drug Metab Dispos 42:520\u2013528. https:\/\/doi.org\/10.1124\/dmd.113.054866","journal-title":"Drug Metab Dispos"},{"key":"3863_CR39","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1002\/cpt.1072","volume":"104","author":"JD Lutz","year":"2018","unstructured":"Lutz JD, Kirby BJ, Wang L et al (2018) Cytochrome P450 3A induction predicts p-glycoprotein induction; Part 2: prediction of decreased substrate exposure after rifabutin or carbamazepine. Clin Pharmacol Ther 104:1191\u20131198. https:\/\/doi.org\/10.1002\/cpt.1072","journal-title":"Clin Pharmacol Ther"},{"key":"3863_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1185\/03007995.2012.747952","volume":"29","author":"AM Baciewicz","year":"2013","unstructured":"Baciewicz AM, Chrisman CR, Finch CK, Self TH (2013) Update on rifampin, rifabutin, and rifapentine drug interactions. Curr Med Res Opin 29:1\u201312. https:\/\/doi.org\/10.1185\/03007995.2012.747952","journal-title":"Curr Med Res Opin"},{"key":"3863_CR41","doi-asserted-by":"publisher","first-page":"e545","DOI":"10.1016\/j.chest.2021.07.055","volume":"160","author":"SM Stevens","year":"2021","unstructured":"Stevens SM, Woller SC, Kreuziger LB et al (2021) Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest 160:e545\u2013e608. https:\/\/doi.org\/10.1016\/j.chest.2021.07.055","journal-title":"Chest"},{"key":"3863_CR42","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","volume":"41","author":"SV Konstantinides","year":"2020","unstructured":"Konstantinides SV, Meyer G, Becattini C et al (2020) 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 41:543\u2013603. https:\/\/doi.org\/10.1093\/eurheartj\/ehz405","journal-title":"Eur Heart J"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03863-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-025-03863-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03863-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T06:23:51Z","timestamp":1753079031000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-025-03863-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,7]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["3863"],"URL":"https:\/\/doi.org\/10.1007\/s00228-025-03863-1","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,7]]},"assertion":[{"value":"23 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}